- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- January 2022
- 60 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Report
- March 2021
- 48 Pages
Global
€21268EUR$22,000USD£18,280GBP
- Report
- January 2019
- 212 Pages
Global
From €21268EUR$22,000USD£18,280GBP
- Report
- March 2018
- 18 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Report
- March 2019
- 195 Pages
Global
From €10629EUR$10,995USD£9,136GBP
- Report
- September 2019
- 70 Pages
Global
From €3142EUR$3,250USD£2,700GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£831GBP
Forteo is a drug used to treat osteoporosis, a condition characterized by low bone density and increased risk of fractures. It is a recombinant human parathyroid hormone (PTH) analog, which stimulates new bone formation and increases bone mineral density. It is used to treat postmenopausal women, men with osteoporosis, and those with glucocorticoid-induced osteoporosis.
Forteo is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to regulate hormones and metabolism, and can be administered orally, intravenously, or topically.
Companies in the Forteo market include Eli Lilly, Novartis, Merck, and Pfizer. Show Less Read more
